Is NeoGenomics, Inc. overvalued or undervalued?

As of 25 February 2022, NeoGenomics, Inc. has moved from a fair to a risky valuation grade. The company is currently overvalued given its financial metrics and peer comparisons. Key ratios include a Price to Book Value of 1.07, an EV to EBIT of -14.14, and an EV to EBITDA of -131.00, indicating significant losses and a lack of profitability.
In comparison to peers, NeoGenomics has an EV to EBITDA ratio of -124.65, while Guardant Health, Inc. shows a similar risky profile with an EV to EBITDA of -15.94. Other peers like RadNet, Inc. are in a different league with a P/E ratio of 132.34, highlighting the disparity in valuation. Additionally, NeoGenomics has underperformed significantly against the S&P 500, with a year-to-date return of -57.46% compared to the index's 2.44%. Overall, the company's financial outlook suggests it is overvalued in the current market context.